Abstract
What can we expect from the implementation of an intra-aortic balloon counterpulsation pump (IABP) in a patient with shock (Fig. 1)? The conventional indication for IABP is cardiogenic shock of ischemic etiology. With the IABP in place in the thoracic aorta, inflation of the balloon in diastole and active deflation in systole induces higher perfusion pressures in the brain and the coronary arteries in diastole and unloads the diseased heart by reducing left ventricular afterload in systole. Of special relevance is the volume shifting of about 40 ml per beat by the IABP, increasing left ventricular ejection fraction and thereby cardiac output in the range of at best 1 l/min.
Patient with myocardial infarction complicated by cardiogenic shock. After treatment with primary percutaneous coronary intervention the patient is still under adjunctive therapy with the intra-aortic balloon counterpulsation (IABP). Written permission obtained from the patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
The Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 29: 2909–2945
Antman EM, Hand M, Armstrong PW, et al (2008) 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am ColI Cardiol 51: 210–247
Stone GW, Ohman EM, Miller MF, et al (2003) Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: The benchmark registry. J Am ColI Cardiol 41: 1940–1945
Santarpino G, Onorati F, Rubino AS, et al (2009) Preoperative intraaortic balloon pumping improves outcomes for high-risk patients in routine coronary artery bypass graft surgery. Ann Thorac Surg 87: 481–488
Hochman IS, Buller CE, Sleeper LA, et al (2000) Cardiogenic shock complicating acute myocardial infarction — etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK? J Am ColI Cardiol 36: 1063–1070
Prondzinsky R, Lemm H, Swyter M, et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock — The Prospective, Randomized IABP SHOCK Trial for Attenuation of Multi-Organ Dysfunction Syndrome. Crit Care Med 38: 152–160
Werdan K, Pilz G, Bujdoso O, et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 35: 2693–2701
Sjauw KD, Engstrom AE, Vis MM, et al (2009) A systematic review and meta-analysis of intraaortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart 130: 459–468
Wilson SR, Mudge GH Ir, Stewart GC, Givertz MM (2009) Evaluation for a ventricular assist device — selecting the appropriate candidate. Circulation 119: 2225–2232
Seyfarth M, Sibbing D, Bauer I, et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardigenic shock caused by myocardial infarction. J Am ColI Cardiol 52: 1584–1588
Combes A, Leprine P, Luyt C-E, et al (2008) Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 36: 1404–1411
Camboni D, Philipp A, Arlt M, Pfeiffer M, Hilker M, Schmid C (2009) First experience with a paracorporal artifical lung in humans. ASAIO 155: 304–306
Thiele H, Sick P, Boudriot E, et al (2005) Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 26: 1276–1283
Chen YS, Lin JW, Yu H-Y, et al (2008) Cardiopulmonary resuscitation with assisted extracorporeallife-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 372: 554–561
Ferrari M, Poerner TC, Brehm BR, et al (2008) First use of a novel plug-and-play percutaneous circulatory assist device for high-risk coronary angioplasty. Acute Card Care 10: 111–115
Cheng JM, den Uil CA, Hoeke SE, et al (2009) Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 30: 2102–2108
Parrillo JE (1989) The cardiovascular pathophysiology of sepsis. Ann Rev Med 40: 469–485
Solomon SB, Minneci PC, Deans KJ, et al (2009) Effects of intra-aortic balloon counterpulsation in a model of septic shock. Crit Care Med 37: 7–18
Müller-Werdan U, Buerke M, Ebelt H, et al (2006) Septic cardiomyopathy — A not yet discovered cardiomyopathy? Exp Clin Cardiol 11: 226–236
Werdan K, Oelke A, Müller-Werdan U (2009) “Myocardial Depression” or “Septic Cardiomyopathy”! In: Vincent JL (ed) 2009 Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg, pp 183–194
Pilz G, McGinn P, Boekstegers P, et al (1994) Pseudomonas sepsis does not cause more severe cardiovascular dysfunction in patients than Non-Pseudomonas sepsis. Circ Shock 42: 174–182
Werdan K (2009) Intra-aortic balloon counterpulsation in septic shock — really? Crit Care Med 37: 325–326
Pribble CG, Shaddy RE (1991) Intra-aortic counterpulsation in newborn lambs infected with group B streptococcus. ASAIO Trans 37: 33–37
Engoren M, Habib RH (2004) Effects of intraaortic augmentation in a porcine model of endotoxemic shock. Resuscitation 60: 319–326
Berger RL, Saini VK, Long W, et al (1973) The use of diastolic augmentation with the intraaortic balloon in human septic shock with associated coronary artery disease. Surgery 74: 601–606
Foster ED, Subramanian VA, Vito L, et al (1975) Response to intra-aortic balloon pumping. Am J Surg 129: 464–471
Mercer D, Doris O, Salerno TA (1981) Intra-aortic balloon counterpulsation in septic shock. Can J Surg 24: 643–645
Kohsaka S, Menon V, Lowe AM, et al (2005) Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165: 1643–1650
Kohsaka S, Menon V, Iwato K, et al (2007) Microbiological profile of septic complications in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK study). Am J Cardiol 99: 802–804
Christoph A, Prondzinsky R, Russ M et al (2008) Early and sustained haemodynamic improvement with levosimendan compared with intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 10: 49–57
Fincke R, Hochman JS, Lowe AM, et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock complicating myocardial infarction. J Am ColI Cardiol 44: 340–346
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science + Business Media Inc.
About this paper
Cite this paper
Werdan, K., Russ, M., Buerke, M. (2010). Intra-aortic Balloon Counterpulsation in Cardiogenic Shock. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5562-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5562-3_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5561-6
Online ISBN: 978-1-4419-5562-3
eBook Packages: MedicineMedicine (R0)